Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Proportional Hazards Models"" wg kryterium: Temat


Tytuł :
Effect of COVID-19 on First-Time Acute Stroke and Transient Ischemic Attack Admission Rates and Prognosis in Denmark: A Nationwide Cohort Study.
Autorzy :
Butt JH; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (J.H.B., E.L.F., L.Ø,A.Y., L.K.).
Fosbøl EL; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (J.H.B., E.L.F., L.Ø,A.Y., L.K.).
Østergaard L; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (J.H.B., E.L.F., L.Ø,A.Y., L.K.).
Yafasova A
Andersson C; Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark (C.A., G.H.G.).; Department of Medicine, Section of Cardiovascular Medicine, Boston Medical Center, Boston University, MA (C.A.).
Schou M; Departments of Cardiology (M.S.), Herlev-Gentofte University Hospital, Herlev, Denmark.
Gerds TA; The Danish Heart Foundation, Copenhagen, Denmark (T.A.G., M.P., G.H.G.).; Department of Biostatistics, University of Copenhagen, Denmark (T.A.G.).
Phelps M; The Danish Heart Foundation, Copenhagen, Denmark (T.A.G., M.P., G.H.G.).
Kruuse C; Neurology (C.K.), Herlev-Gentofte University Hospital, Herlev, Denmark.
Gislason GH; Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark (C.A., G.H.G.).; The Danish Heart Foundation, Copenhagen, Denmark (T.A.G., M.P., G.H.G.).
Torp-Pedersen C; Department of Clinical Research and Cardiology, Nordsjællands Hospital, Hillerød, Denmark (C.T.-P.).
Køber L; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (J.H.B., E.L.F., L.Ø,A.Y., L.K.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2020 Sep 22; Vol. 142 (12), pp. 1227-1229. Date of Electronic Publication: 2020 Aug 05.
Typ publikacji :
Letter
MeSH Terms :
Coronavirus Infections/*pathology
Ischemic Attack, Transient/*diagnosis
Pneumonia, Viral/*pathology
Stroke/*diagnosis
Betacoronavirus/isolation & purification ; Cohort Studies ; Coronavirus Infections/complications ; Coronavirus Infections/virology ; Denmark/epidemiology ; Hospitalization ; Humans ; Incidence ; Ischemic Attack, Transient/complications ; Ischemic Attack, Transient/epidemiology ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/virology ; Prognosis ; Proportional Hazards Models ; Stroke/complications ; Stroke/epidemiology
SCR Disease Name :
COVID-19
Opinia redakcyjna
Tytuł :
Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies.
Autorzy :
McCaw ZR; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA (Z.R.M., L.J.W.).
Yin G; Department of Statistics and Actuarial Science, The University of Hong Kong, China (G.Y.).
Wei LJ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA (Z.R.M., L.J.W.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2019 Oct 22; Vol. 140 (17), pp. 1366-1368. Date of Electronic Publication: 2019 Oct 21.
Typ publikacji :
Journal Article
MeSH Terms :
Proportional Hazards Models*
Survival Rate*
Cardiovascular Diseases/*mortality
Coronary Artery Disease/*mortality
Aged ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight Against COVID-19.
Autorzy :
Chapman AR; British Heart Foundation Centre for Cardiovascular Science (A.R.C., A.B., N.L.M.), University of Edinburgh, United Kingdom.
Bularga A; British Heart Foundation Centre for Cardiovascular Science (A.R.C., A.B., N.L.M.), University of Edinburgh, United Kingdom.
Mills NL; British Heart Foundation Centre for Cardiovascular Science (A.R.C., A.B., N.L.M.), University of Edinburgh, United Kingdom.; Usher Institute of Population Health Sciences and Informatics (N.L.M.), University of Edinburgh, United Kingdom.
Pokaż więcej
Źródło :
Circulation [Circulation] 2020 Jun 02; Vol. 141 (22), pp. 1733-1735. Date of Electronic Publication: 2020 Apr 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Coronavirus Infections/*pathology
Myocardium/*metabolism
Pneumonia, Viral/*pathology
Troponin I/*analysis
Acute Kidney Injury/diagnosis ; Acute Kidney Injury/etiology ; Betacoronavirus/isolation & purification ; Coronavirus Infections/complications ; Coronavirus Infections/virology ; Fibrin Fibrinogen Degradation Products/analysis ; Humans ; Lymphocyte Count ; Myocardial Infarction/diagnosis ; Myocardial Infarction/etiology ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/virology ; Proportional Hazards Models ; Respiratory Distress Syndrome, Adult/diagnosis ; Respiratory Distress Syndrome, Adult/etiology
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.
Autorzy :
Sorrentino S; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Claessen BE; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Chandiramani R; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Guedeney P; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Vogel B; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Baber U; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Rau V; Abbott Vascular, Santa Clara, CA (V.R., J.W.).
Wang J; Abbott Vascular, Santa Clara, CA (V.R., J.W.).
Krucoff M; Duke University Medical Center, Durham, NC (M.K.).
Kozuma K; Teikyo University, Tokyo, Japan (K.K.).
Ge J; Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China (J.G.).
Seth A; Fortis Escorts Heart Institute, New Delhi, India (A.S.).
Makkar R; Cedars-Sinai Medical Center, Los Angeles, CA (R. Makkar).
Liu Y; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Bangalore S; New York University Langone Medical Center (S.B.).
Bhatt DL; Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.).
Angiolillo DJ; University of Florida College of Medicine-Jacksonville (D.J.A.).
Saito S; Shonan Kamakura General Hospital, Japan (S.S.).
Neumann FJ; University of Freiburg, Germany (F.-J.N.).
Hermiller J; St Vincent's Medical Center of Indiana, Indianapolis (J.H.).
Valgimigli M; Bern University Hospital, Switzerland (M.V.).
Mehran R; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Pokaż więcej
Źródło :
Circulation [Circulation] 2020 Mar 17; Vol. 141 (11), pp. 891-901. Date of Electronic Publication: 2020 Jan 29.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Coronary Stenosis/*therapy
Coronary Thrombosis/*etiology
Drug-Eluting Stents/*adverse effects
Everolimus/*adverse effects
Hemorrhage/*etiology
Myocardial Infarction/*etiology
Percutaneous Coronary Intervention/*instrumentation
Aged ; Aged, 80 and over ; Cause of Death ; Chromium ; Cobalt ; Comorbidity ; Coronary Restenosis/epidemiology ; Coronary Restenosis/etiology ; Coronary Stenosis/complications ; Coronary Thrombosis/epidemiology ; Drug Therapy, Combination ; Everolimus/administration & dosage ; Everolimus/therapeutic use ; Female ; Hemorrhage/epidemiology ; Hemorrhagic Disorders/epidemiology ; Humans ; Kaplan-Meier Estimate ; Male ; Metabolic Syndrome/epidemiology ; Middle Aged ; Mortality ; Myocardial Infarction/epidemiology ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/therapeutic use ; Polymers ; Prevalence ; Proportional Hazards Models ; Prospective Studies ; Registries ; Smoking/epidemiology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Autorzy :
Damask A; Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
Steg PG; Université de Paris, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, INSERM U1148, France (P.G.S.).
Schwartz GG; University of Colorado School of Medicine, Aurora (G.G.S.).
Szarek M; Department of Biostatistics and Epidemiology, SUNY Downstate School of Public Health, Brooklyn, NY (M.S.).
Hagström E; Department of Medical Sciences, Cardiology, Uppsala University, Sweden (E.H.).
Badimon L; Cardiovascular Program-ICCC, CiberCV, IR-Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (L.B.).
Chapman MJ; Endocrinology Metabolism Division, Pitie-Salpetriere University Hospital, Sorbonne University and National Institute for Health and Medical Research (INSERM), Paris, France (M.J.C.).
Boileau C; Université de Paris, INSERM U1148 and Genetics Department, APHP-Hospital Bichat-Claude Bernard, France (C.B.).
Tsimikas S; Sulpizio Cardiovascular Center, Division of Cardiovascular Medicine, University of California San Diego, La Jolla (S.T.).
Ginsberg HN; Irving Institute for Clinical and Translational Research, Columbia University, New York (H.N.G.).
Banerjee P; Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
Manvelian G; Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
Pordy R; Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
Hess S; Sanofi Aventis Deutschland GmbH, Translational Medicine and Early Development, Biomarkers and Clinical Bioanalyses, Frankfurt, Germany (S.H.).
Overton JD; Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
Lotta LA; Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
Yancopoulos GD; Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
Abecasis GR; Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
Baras A; Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
Paulding C; Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
Pokaż więcej
Corporate Authors :
Regeneron Genetics Center and the ODYSSEY OUTCOMES Investigators
Źródło :
Circulation [Circulation] 2020 Feb 25; Vol. 141 (8), pp. 624-636. Date of Electronic Publication: 2019 Nov 11.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Anticholesteremic Agents/*therapeutic use
Coronary Artery Disease/*genetics
Multifactorial Inheritance/*genetics
Proprotein Convertase 9/*genetics
Aged ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/epidemiology ; Cholesterol, LDL/blood ; Coronary Artery Disease/drug therapy ; Double-Blind Method ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypercholesterolemia/prevention & control ; Male ; Middle Aged ; Placebo Effect ; Proportional Hazards Models ; Proprotein Convertase 9/antagonists & inhibitors ; Proprotein Convertase 9/metabolism ; Risk Factors
Czasopismo naukowe
Tytuł :
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.
Autorzy :
Marston NA; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., F.K.K., F.N., Y.G., R.P.G., M.S.S., C.T.R.).
Kamanu FK; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., F.K.K., F.N., Y.G., R.P.G., M.S.S., C.T.R.).
Nordio F; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., F.K.K., F.N., Y.G., R.P.G., M.S.S., C.T.R.).
Gurmu Y; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., F.K.K., F.N., Y.G., R.P.G., M.S.S., C.T.R.).
Roselli C; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard Cambridge, MA (C.R., S.A.L., P.T.E.).; University Medical Center Groningen, University of Groningen, the Netherlands (C.R.).
Sever PS; National Heart and Lung Institute, Imperial College London, United Kingdom (P.S.S.).
Pedersen TR; Oslo University Hospital, Ulleval and Medical Faculty, University of Oslo, Norway (T.R.P.).
Keech AC; Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia (A.C.K.).
Wang H; Amgen, Thousand Oaks, CA (H.W., A.L.P.).
Lira Pineda A; Amgen, Thousand Oaks, CA (H.W., A.L.P.).
Giugliano RP; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., F.K.K., F.N., Y.G., R.P.G., M.S.S., C.T.R.).
Lubitz SA; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard Cambridge, MA (C.R., S.A.L., P.T.E.).; Cardiovascular Research Center, Massachusetts General Hospital, Boston (S.A.L., P.T.E.).
Ellinor PT; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard Cambridge, MA (C.R., S.A.L., P.T.E.).; Cardiovascular Research Center, Massachusetts General Hospital, Boston (S.A.L., P.T.E.).
Sabatine MS; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., F.K.K., F.N., Y.G., R.P.G., M.S.S., C.T.R.).
Ruff CT; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., F.K.K., F.N., Y.G., R.P.G., M.S.S., C.T.R.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2020 Feb 25; Vol. 141 (8), pp. 616-623. Date of Electronic Publication: 2019 Nov 11.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Anticholesteremic Agents/*therapeutic use
Atherosclerosis/*drug therapy
Proprotein Convertase 9/*genetics
Adult ; Aged ; Aged, 80 and over ; Atherosclerosis/genetics ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/etiology ; Cholesterol, LDL/blood ; Double-Blind Method ; Female ; Follow-Up Studies ; Genotype ; Humans ; Male ; Middle Aged ; Placebo Effect ; Polymorphism, Single Nucleotide ; Proportional Hazards Models ; Proprotein Convertase 9/antagonists & inhibitors ; Proprotein Convertase 9/metabolism ; Risk Factors
Czasopismo naukowe
Tytuł :
Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis.
Autorzy :
Bick AG; Cardiovascular Research Center (A.G.B., J.P.P., P.N.), Massachusetts General Hospital, Boston.; Center for Genomic Medicine (A.G.B., J.P.P., S.K., P.N.), Massachusetts General Hospital, Boston.; Department of Medicine (A.G.B., J.P.P., S.K., P.N.), Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge (A.G.B., J.P.P., G.K.G., N.G., S.G., S.K., P.N.).
Pirruccello JP; Cardiovascular Research Center (A.G.B., J.P.P., P.N.), Massachusetts General Hospital, Boston.; Center for Genomic Medicine (A.G.B., J.P.P., S.K., P.N.), Massachusetts General Hospital, Boston.; Department of Medicine (A.G.B., J.P.P., S.K., P.N.), Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge (A.G.B., J.P.P., G.K.G., N.G., S.G., S.K., P.N.).
Griffin GK; Department of Pathology (G.K.G.), Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge (A.G.B., J.P.P., G.K.G., N.G., S.G., S.K., P.N.).; Department of Pathology (G.K.G.), Brigham and Women's Hospital, Boston, MA.
Gupta N; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge (A.G.B., J.P.P., G.K.G., N.G., S.G., S.K., P.N.).
Gabriel S; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge (A.G.B., J.P.P., G.K.G., N.G., S.G., S.K., P.N.).
Saleheen D; Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.S.).; Center for Non-Communicable Diseases, Karachi, Pakistan (D.S.).
Libby P; Division of Cardiology (P.L.), Brigham and Women's Hospital, Boston, MA.
Kathiresan S; Center for Genomic Medicine (A.G.B., J.P.P., S.K., P.N.), Massachusetts General Hospital, Boston.; Department of Medicine (A.G.B., J.P.P., S.K., P.N.), Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge (A.G.B., J.P.P., G.K.G., N.G., S.G., S.K., P.N.).; Verve Therapeutics, Cambridge, MA (S.K.).
Natarajan P; Cardiovascular Research Center (A.G.B., J.P.P., P.N.), Massachusetts General Hospital, Boston.; Center for Genomic Medicine (A.G.B., J.P.P., S.K., P.N.), Massachusetts General Hospital, Boston.; Department of Medicine (A.G.B., J.P.P., S.K., P.N.), Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge (A.G.B., J.P.P., G.K.G., N.G., S.G., S.K., P.N.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2020 Jan 14; Vol. 141 (2), pp. 124-131. Date of Electronic Publication: 2019 Nov 11.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Cardiovascular Diseases/*pathology
Interleukin-6/*metabolism
Receptors, Interleukin-6/*genetics
Aged ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/genetics ; Clonal Evolution ; Female ; Hematopoiesis ; Humans ; Incidence ; Male ; Middle Aged ; Polymorphism, Single Nucleotide ; Proportional Hazards Models ; Prospective Studies ; Risk Factors ; Signal Transduction
Czasopismo naukowe
Tytuł :
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Autorzy :
Kosiborod MN; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City (M.N.K.).; The George Institute for Global Health and University of New South Wales, Sydney, Australia (M.N.K).
Jhund PS; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK (P.S.J., K.F.D., M.C.P., J.J.V.M.).
Docherty KF; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK (P.S.J., K.F.D., M.C.P., J.J.V.M.).
Diez M; Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Argentina (M.D.).
Petrie MC; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK (P.S.J., K.F.D., M.C.P., J.J.V.M.).
Verma S; St Michael's Hospital, University of Toronto, Canada (S.V.).
Nicolau JC; Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, Brazil (J.C.N.).
Merkely B; Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.).
Kitakaze M; Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center, Suita Osaka, Japan (M.K.).
DeMets DL; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison (D.L.D.).
Inzucchi SE; Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.).
Køber L; Rigshospitalet, Department of Cardiology, University of Copenhagen, Denmark (L.K.).
Martinez FA; Universidad Nacional de Córdoba, Argentina (F.A.M.).
Ponikowski P; Center for Heart Diseases, University Hospital, Wroclaw Medical University, Poland (P.P.).
Sabatine MS; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (M.S.S., S.D.S.).
Solomon SD; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (M.S.S., S.D.S.).
Bengtsson O; Late Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., D.L., A.N., M.S., A.M.L.).
Lindholm D; Late Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., D.L., A.N., M.S., A.M.L.).
Niklasson A; Late Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., D.L., A.N., M.S., A.M.L.).
Sjöstrand M; Late Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., D.L., A.N., M.S., A.M.L.).
Langkilde AM; Late Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., D.L., A.N., M.S., A.M.L.).
McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK (P.S.J., K.F.D., M.C.P., J.J.V.M.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2020 Jan 14; Vol. 141 (2), pp. 90-99. Date of Electronic Publication: 2019 Nov 17.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Quality of Life*
Ventricular Function, Left*/drug effects
Benzhydryl Compounds/*therapeutic use
Glucosides/*therapeutic use
Heart Failure/*drug therapy
Aged ; Benzhydryl Compounds/pharmacology ; Female ; Glucosides/pharmacology ; Heart Failure/mortality ; Heart Failure/pathology ; Hospitalization/statistics & numerical data ; Humans ; Male ; Middle Aged ; Odds Ratio ; Placebo Effect ; Proportional Hazards Models ; Prospective Studies ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Childhood Risk Factors Contribute to Cardiovascular Events in Adults.
Autorzy :
Kuehn BM
Pokaż więcej
Źródło :
Circulation [Circulation] 2020 Jan 14; Vol. 141 (2), pp. 147-148. Date of Electronic Publication: 2020 Jan 13.
Typ publikacji :
Wiadomości
MeSH Terms :
Cardiovascular Diseases/*diagnosis
Adolescent ; Adult ; Body Mass Index ; Cardiovascular Diseases/etiology ; Child ; Cholesterol/blood ; Congresses as Topic ; Female ; Humans ; Male ; Proportional Hazards Models ; Risk Factors
Periodyk
Tytuł :
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
Autorzy :
Martinez FA; Universidad Nacional de Córdoba, Argentina (F.M.).
Serenelli M; BHF Cardiovascular Research Centre, University of Glasgow, UK (M. Serenelli, M.C.P., P.J., J.J.V.M.).; Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy (M. Serenelli).
Nicolau JC; Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil (J.C.N.).
Petrie MC; BHF Cardiovascular Research Centre, University of Glasgow, UK (M. Serenelli, M.C.P., P.J., J.J.V.M.).
Chiang CE; General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taiwan (C.E.-C.).
Tereshchenko S; Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology of Russia, Moscow (S.T.).
Solomon SD; Division of Cardiovascular Medicine (S.D.S.), Brigham and Women's Hospital, Boston, MA.
Inzucchi SE; Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.).
Køber L; Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Denmark (L.K.).
Kosiborod MN; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City (M.N.K.).; The George Institute for Global Health, University of New South Wales, Sydney, Australia (M.N.K.).
Ponikowski P; Center for Heart Diseases, University Hospital, Wroclaw Medical University, Poland (P.P.).
Sabatine MS; TIMI Study Group (M.S.S.), Brigham and Women's Hospital, Boston, MA.
DeMets DL; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison (D.L.D.).
Dutkiewicz-Piasecka M; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland (M.D.-P.).
Bengtsson O; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., M. Söjstrand, A.M.L.).
Sjöstrand M; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., M. Söjstrand, A.M.L.).
Langkilde AM; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., M. Söjstrand, A.M.L.).
Jhund PS; BHF Cardiovascular Research Centre, University of Glasgow, UK (M. Serenelli, M.C.P., P.J., J.J.V.M.).
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, UK (M. Serenelli, M.C.P., P.J., J.J.V.M.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2020 Jan 14; Vol. 141 (2), pp. 100-111. Date of Electronic Publication: 2019 Nov 17.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Ventricular Function, Left*/drug effects
Benzhydryl Compounds/*therapeutic use
Glucosides/*therapeutic use
Heart Failure/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Benzhydryl Compounds/pharmacology ; Female ; Glucosides/pharmacology ; Heart Failure/mortality ; Heart Failure/pathology ; Hospitalization ; Humans ; Male ; Middle Aged ; Natriuretic Peptide, Brain/analysis ; Peptide Fragments/analysis ; Placebo Effect ; Proportional Hazards Models ; Survival Analysis ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Autorzy :
Windecker S; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Switzerland (S.W.).
Lopes RD; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L., T.M., C.B.G., G.H., W.S.J., J.H.A.).
Massaro T; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L., T.M., C.B.G., G.H., W.S.J., J.H.A.).
Jones-Burton C; Bristol-Myers Squibb, Lawrenceville, NJ (C.J.-B., R.A.).
Granger CB; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L., T.M., C.B.G., G.H., W.S.J., J.H.A.).
Aronson R; Bristol-Myers Squibb, Lawrenceville, NJ (C.J.-B., R.A.).
Heizer G; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L., T.M., C.B.G., G.H., W.S.J., J.H.A.).
Goodman SG; Canadian VIGOUR Center, University of Alberta, Edmonton, Canada (S.G.G., R.C.W.).; Terrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto, Ontario, Canada (S.G.G.).
Darius H; Vivantes Neukoelln Medical Center, Berlin, Germany (H.D.).
Jones WS; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L., T.M., C.B.G., G.H., W.S.J., J.H.A.).
Aschermann M; Charles University, Prague, Czech Republic (M.A.).
Brieger D; Concord Clinical School, ANZAC Research Institute, University of Sydney, Australia (D.B.).
Cura F; Instituto Cardiovascular de Buenos Aires and Sanatorio Anchorena, Argentina (F.C.).
Engstrøm T; Rigshospital, University of Copenhagen, Denmark (T.E.).
Fridrich V; National Institute of Cardiovascular Diseases, Bratislava, Slovakia (V.F.).
Halvorsen S; Oslo University Hospital Ulleval, University of Oslo, Norway (S.H.).
Huber K; Wilhelminenhospital and Sigmund Freud University, Medical School, Vienna, Austria (K.H.).
Kang HJ; Seoul National University Hospital, Seoul National University, Korea (H.-J.K.).
Leiva-Pons JL; Hospital Central Dr Ignacio Morones Prieto, San Luis Potosi, Mexico (J.L.L.-P.).
Lewis BS; Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel (B.S.L.).
Malaga G; CONEVID School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru (G.M.).
Meneveau N; University Hospital Jean Minjoz, Besançon, France (N.M.).; EA3920, University of Burgundy Franche-Comté, Besançon, France (N.M.).
Merkely B; Semmelweis University Heart and Vascular Center, Budapest, Hungary (B.M.).
Milicic D; University of Zagreb School of Medicine, University Hospital Centre, Croatia (D.M.).
Morais J; Hospital de Santo André, Leiria, Portugal (J.M.).
Potpara TS; School of Medicine, Belgrade University, Serbia (T.S.P.).; Clinical Centre of Serbia, Belgrade (T.S.P.).
Raev D; University Hospital St Anna, Sofia, Bulgaria (D.R.).
Sabaté M; University Heart Centre Lübeck, University Hospital Schleswig-Holstein, Germany (S.d.W.-T.).
de Waha-Thiele S; German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Lübeck (S.d.W.-T.).
Welsh RC; Canadian VIGOUR Center, University of Alberta, Edmonton, Canada (S.G.G., R.C.W.).; Mazankowski Alberta Heart Institute, Edmonton, Canada (R.C.W.).
Xavier D; St John's Medical College and Research Institute, Bangalore, India (D.X.).
Mehran R; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, and Cardiovascular Research Foundation, New York, NY (R.M.).
Alexander JH; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L., T.M., C.B.G., G.H., W.S.J., J.H.A.).
Pokaż więcej
Corporate Authors :
AUGUSTUS Investigators
Źródło :
Circulation [Circulation] 2019 Dec 03; Vol. 140 (23), pp. 1921-1932. Date of Electronic Publication: 2019 Sep 26.
Typ publikacji :
Clinical Trial; Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Percutaneous Coronary Intervention*
Acute Coronary Syndrome/*drug therapy
Anticoagulants/*therapeutic use
Aspirin/*therapeutic use
Atrial Fibrillation/*drug therapy
Cardiovascular Agents/*therapeutic use
Fibrinolytic Agents/*therapeutic use
Platelet Aggregation Inhibitors/*therapeutic use
Pyrazoles/*therapeutic use
Pyridones/*therapeutic use
Acute Coronary Syndrome/complications ; Acute Coronary Syndrome/surgery ; Aged ; Anticoagulants/adverse effects ; Atrial Fibrillation/complications ; Combined Modality Therapy ; Disease Management ; Drug Therapy, Combination ; Elective Surgical Procedures ; Female ; Fibrinolytic Agents/adverse effects ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Hospitalization ; Humans ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/adverse effects ; Proportional Hazards Models ; Prospective Studies ; Purinergic P2Y Receptor Antagonists/adverse effects ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Treatment Outcome ; Vitamin K/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
Autorzy :
Vora AN; UPMC Pinnacle, Harrisburg, PA (A.N.V.).; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.N.V., J.H.A., D.M.W., C.B.G., D.F.K., R.H.M., R.D.L.).
Alexander JH; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.N.V., J.H.A., D.M.W., C.B.G., D.F.K., R.H.M., R.D.L.).
Wojdyla DM; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.N.V., J.H.A., D.M.W., C.B.G., D.F.K., R.H.M., R.D.L.).
Aronson R; Bristol-Myers Squibb, Lawrenceville, NJ (R.A.).
Granger CB; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.N.V., J.H.A., D.M.W., C.B.G., D.F.K., R.H.M., R.D.L.).
Darius H; Vivantes Neukoelln Medical Center, Berlin, Germany (H.D.).
Windecker S; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Switzerland (S.W.).
Mehran R; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, and Cardiovascular Research Foundation, New York (R.M.).
Averkov O; Pirogov Russian National Research Medical University, Moscow (O.A.).
Budaj A; Department of Cardiology, Grochowski Hospital, Warsaw, Poland (A.B.).
Kong DF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.N.V., J.H.A., D.M.W., C.B.G., D.F.K., R.H.M., R.D.L.).
Kobalava Z; RUDN University, Moscow, Russia (Z.K.).
Mehta RH; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.N.V., J.H.A., D.M.W., C.B.G., D.F.K., R.H.M., R.D.L.).
Mirza Z; Witham Specialist Center, Lebanon, IN (Z.M.).
Guimaraes PO; Instituto do Coração-HCFMUSP, São Paulo, Brazil (P.O.G.).
Parkhomenko A; Emergency Cardiology Department, Institute of Cardiology, Kiev, Ukraine (A.P.).
Quadros A; Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil (A.Q.).
Thiele H; Heart Center Leipzig at University of Leipzig, Germany (H.T.).
Goodman SG; Canadian VIGOUR Center, University of Alberta, Edmonton (S.G.G.).; Terrence Donnelly Heart Centre, St. Michael's Hospital, University of Toronto, ON, Canada (S.G.G.).
Lopes RD; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.N.V., J.H.A., D.M.W., C.B.G., D.F.K., R.H.M., R.D.L.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2019 Dec 03; Vol. 140 (23), pp. 1960-1963. Date of Electronic Publication: 2019 Sep 25.
Typ publikacji :
Comparative Study; Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Percutaneous Coronary Intervention*
Acute Coronary Syndrome/*drug therapy
Anticoagulants/*therapeutic use
Aspirin/*therapeutic use
Atrial Fibrillation/*drug therapy
Cardiovascular Agents/*therapeutic use
Fibrinolytic Agents/*therapeutic use
Hospitalization/*statistics & numerical data
Platelet Aggregation Inhibitors/*therapeutic use
Pyrazoles/*therapeutic use
Pyridones/*therapeutic use
Acute Coronary Syndrome/complications ; Acute Coronary Syndrome/surgery ; Aged ; Anticoagulants/adverse effects ; Atrial Fibrillation/complications ; Combined Modality Therapy ; Drug Therapy, Combination ; Elective Surgical Procedures ; Female ; Fibrinolytic Agents/adverse effects ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Humans ; Length of Stay/statistics & numerical data ; Male ; Middle Aged ; Multicenter Studies as Topic/statistics & numerical data ; Platelet Aggregation Inhibitors/adverse effects ; Proportional Hazards Models ; Prospective Studies ; Purinergic P2Y Receptor Antagonists/adverse effects ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Randomized Controlled Trials as Topic/statistics & numerical data ; Survival Analysis ; Treatment Outcome ; Vitamin K/antagonists & inhibitors
Raport
Tytuł :
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial.
Autorzy :
Watanabe H; Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Japan (H.W., H. Shiomi, T.K.).
Domei T; Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan (T.D., K.A.).
Morimoto T; Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan (T.M.).
Natsuaki M; Department of Cardiovascular Medicine, Saga University, Japan (M.N.).
Shiomi H; Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Japan (H.W., H. Shiomi, T.K.).
Toyota T; Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Japan (T. Toyota, Y.F.).
Ohya M; Department of Cardiology, Kurashiki Central Hospital, Japan (M.O., K. Kadota).
Suwa S; Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, Japan (S.S.).
Takagi K; Department of Cardiology, Ogaki Municipal Hospital, Japan (K. Takagi).
Nanasato M; Department of Cardiology, Sakakibara Heart Institute, Fuchu, Japan (M.N., I.T.).
Hata Y; Department of Cardiology, Minamino Cardiovascular Hospital, Hachioji, Japan (Y.H.).
Yagi M; Department of Cardiology, Sendai Cardiovascular Center, Japan (M.Y.).
Suematsu N; Department of Cardiology, Saiseikai Fukuoka General Hospital, Japan (N.S.).
Yokomatsu T; Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan (T.Y.).
Takamisawa I; Department of Cardiology, Sakakibara Heart Institute, Fuchu, Japan (M.N., I.T.).
Doi M; Department of Cardiology, Kagawa Prefectural Central Hospital, Takamatsu, Japan (M.D.).
Noda T; Department of Cardiology, Gifu Prefectural General Medical Center, Japan (T.N.).
Okayama H; Department of Cardiology, Ehime Prefectural Central Hospital, Matsuyama, Japan (H.O.).
Seino Y; Department of Cardiology, Hoshi General Hospital, Koriyama, Japan (Y.S.).
Tada T; Department of Cardiology, Shizuoka General Hospital, Japan (T. Tada, H. Sakamoto).
Sakamoto H; Department of Cardiology, Shizuoka General Hospital, Japan (T. Tada, H. Sakamoto).
Hibi K; Division of Cardiology, Yokohama City University Medical Center, Japan (K.H.).
Abe M; Department of Cardiology, National Hospital Organization Kyoto Medical Center, Japan (M.A.).
Kawai K; Department of Cardiology, Chikamori Hospital, Kochi, Japan (K. Kawai).
Nakao K; Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Japan (K.N.).
Ando K; Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan (T.D., K.A.).
Tanabe K; Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan (K. Tanabe).
Ikari Y; Department of Cardiology, Tokai University Hospital, Isehara, Japan (Y.I.).
Hanaoka KI; Hanaoka Seishu Memorial Cardiovascular Clinic, Sapporo, Japan (K.I.H.).
Morino Y; Department of Cardiology, Iwate Medical University Hospital, Morioka, Japan (Y.M.).
Kozuma K; Department of Cardiology, Teikyo University Hospital, Tokyo, Japan (K. Kozuma).
Kadota K; Department of Cardiology, Kurashiki Central Hospital, Japan (M.O., K. Kadota).
Furukawa Y; Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Japan (T. Toyota, Y.F.).
Nakagawa Y; Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan (Y.N.).
Kimura T; Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Japan (H.W., H. Shiomi, T.K.).
Pokaż więcej
Corporate Authors :
STOPDAPT-2 Investigators
Źródło :
Circulation [Circulation] 2019 Dec 03; Vol. 140 (23), pp. 1957-1959. Date of Electronic Publication: 2019 Sep 27.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Aspirin/*therapeutic use
Clopidogrel/*therapeutic use
Everolimus/*therapeutic use
Hemorrhage/*prevention & control
Multicenter Studies as Topic/*statistics & numerical data
Platelet Aggregation Inhibitors/*therapeutic use
Randomized Controlled Trials as Topic/*statistics & numerical data
Aged ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Chromium Alloys ; Clopidogrel/administration & dosage ; Clopidogrel/adverse effects ; Coronary Restenosis/epidemiology ; Coronary Restenosis/etiology ; Drug Administration Schedule ; Drug Therapy, Combination ; Drug-Eluting Stents ; Everolimus/administration & dosage ; Female ; Hemorrhage/chemically induced ; Humans ; Incidence ; Japan/epidemiology ; Male ; Middle Aged ; Myocardial Infarction/epidemiology ; Myocardial Infarction/etiology ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/adverse effects ; Postoperative Complications/epidemiology ; Postoperative Complications/etiology ; Postoperative Complications/prevention & control ; Proportional Hazards Models ; Single-Blind Method ; Stroke/epidemiology ; Stroke/etiology
Raport
Tytuł :
Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients With Peripheral Artery Disease?
Autorzy :
Beckman JA; Vanderbilt University Medical Center, Nashville, TN (J.A.B.).
White CJ; Ochsner Health System, New Orleans, LA (C.J.W.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2019 Oct 15; Vol. 140 (16), pp. 1342-1351. Date of Electronic Publication: 2019 Jun 10.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Phytogenic/*chemistry
Drug-Eluting Stents/*adverse effects
Paclitaxel/*chemistry
Peripheral Arterial Disease/*etiology
Antineoplastic Agents, Phytogenic/therapeutic use ; Consensus ; Humans ; Meta-Analysis as Topic ; Neoplasms/drug therapy ; Paclitaxel/therapeutic use ; Peripheral Arterial Disease/mortality ; Proportional Hazards Models ; Survival Analysis
Czasopismo naukowe
Tytuł :
Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years.
Autorzy :
Gray WA; Lankenau Heart Institute/Main Line Health, Philadelphia, PA (W.A.G.).
Jaff MR; Newton-Wellesley Hospital, MA (M.R.J.).
Parikh SA; New York Presbyterian Hospital, Columbia University Irving Medical Center (S.A.P.).
Ansel GM; OhioHealth Heart and Vascular Physicians, Columbus (G.M.A.).
Brodmann M; Medical University Graz, Austria (M.B.).
Krishnan P; Mount Sinai Hospital, New York (P.K.).
Razavi MK; St. Joseph Health, Orange, CA (M.K.R.).
Vermassen F; Ghent University Hospital, Belgium (F.V.).
Zeller T; Universitäts - Herzzentrum, Freiburg, Germany (T.Z.).
White R; Syntactx, New York (R.W., K.O., M.A.A.).
Ouriel K; Syntactx, New York (R.W., K.O., M.A.A.).
Adelman MA; Syntactx, New York (R.W., K.O., M.A.A.).
Lyden SP; Cleveland Clinic, OH (S.P.L.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2019 Oct; Vol. 140 (14), pp. 1145-1155. Date of Electronic Publication: 2019 Sep 30.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug-Eluting Stents/*adverse effects
Paclitaxel/*chemistry
Peripheral Arterial Disease/*drug therapy
Aged ; Angioplasty/adverse effects ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Paclitaxel/therapeutic use ; Peripheral Arterial Disease/mortality ; Peripheral Arterial Disease/therapy ; Proportional Hazards Models ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of Linked Electronic Health Records: A CALIBER Study.
Autorzy :
Leon LJ; Department of Women and Children's Health, King's College London, United Kingdom (L.J.L., F.P.M., L.C.).; Institute of Health Informatics, University College London, United Kingdom (L.J.L., K.D., A.G.I., D.P.M.).
McCarthy FP; Department of Women and Children's Health, King's College London, United Kingdom (L.J.L., F.P.M., L.C.).; The Irish Centre for Fetal and Neonatal Translational Research, University College Cork, Cork University Maternity Hospital, Cork, Ireland (F.P.M.).
Direk K; Institute of Health Informatics, University College London, United Kingdom (L.J.L., K.D., A.G.I., D.P.M.).
Gonzalez-Izquierdo A; Institute of Health Informatics, University College London, United Kingdom (L.J.L., K.D., A.G.I., D.P.M.).
Prieto-Merino D; Institute of Health Informatics, University College London, United Kingdom (L.J.L., K.D., A.G.I., D.P.M.).; Applied Statistical Methods in Medical Research Group, Universidad Catolica San Antonio de Murcia, Spain (D.P.M.).
Casas JP; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare, MA (J.P.C.).
Chappell L; Department of Women and Children's Health, King's College London, United Kingdom (L.J.L., F.P.M., L.C.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2019 Sep 24; Vol. 140 (13), pp. 1050-1060. Date of Electronic Publication: 2019 Sep 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Population Groups*
Cardiovascular Diseases/*epidemiology
Pre-Eclampsia/*epidemiology
Adult ; Cohort Studies ; Electronic Health Records ; Female ; Humans ; Incidence ; Pregnancy ; Proportional Hazards Models ; United Kingdom/epidemiology
Czasopismo naukowe
Tytuł :
Exercise-Induced Cardiac Troponin I Increase and Incident Mortality and Cardiovascular Events.
Autorzy :
Aengevaeren VL; Departments of Physiology (V.L.A., M.T.E.H., E.A.B., D.H.J.T., T.M.H.E.), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.; Cardiology (V.L.A.), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Hopman MTE; Departments of Physiology (V.L.A., M.T.E.H., E.A.B., D.H.J.T., T.M.H.E.), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Thompson PD; Division of Cardiology, Hartford Hospital, CT (P.D.T.).
Bakker EA; Departments of Physiology (V.L.A., M.T.E.H., E.A.B., D.H.J.T., T.M.H.E.), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.; Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, UK (E.A.B., K.P.G., D.H.J.T., T.M.H.E.).
George KP; Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, UK (E.A.B., K.P.G., D.H.J.T., T.M.H.E.).
Thijssen DHJ; Departments of Physiology (V.L.A., M.T.E.H., E.A.B., D.H.J.T., T.M.H.E.), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.; Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, UK (E.A.B., K.P.G., D.H.J.T., T.M.H.E.).
Eijsvogels TMH; Departments of Physiology (V.L.A., M.T.E.H., E.A.B., D.H.J.T., T.M.H.E.), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.; Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, UK (E.A.B., K.P.G., D.H.J.T., T.M.H.E.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2019 Sep 09; Vol. 140 (10), pp. 804-814. Date of Electronic Publication: 2019 Aug 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers/*blood
Myocardial Infarction/*diagnosis
Troponin T/*blood
Aged ; Cohort Studies ; Endurance Training ; Female ; Humans ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Predictive Value of Tests ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Walking
Czasopismo naukowe
Tytuł :
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Autorzy :
Mahaffey KW; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (K.W.M.).
Jardine MJ; George Institute for Global Health, University of New South Wales, Sydney, Australia (M.J.J., S.B., B.N., H.J.L.H., V.P.).; Concord Repatriation General Hospital, Sydney, Australia (M.J.J.).
Bompoint S; George Institute for Global Health, University of New South Wales, Sydney, Australia (M.J.J., S.B., B.N., H.J.L.H., V.P.).
Cannon CP; Cardiovascular Division, Brigham & Women's Hospital, Boston, MA (C.P.C.).; Baim Institute for Clinical Research, Boston, MA (D.M.C., C.P.C., B.M.B.).
Neal B; George Institute for Global Health, University of New South Wales, Sydney, Australia (M.J.J., S.B., B.N., H.J.L.H., V.P.).; Charles Perkins Centre, University of Sydney, Australia (B.N.).; Imperial College London, UK (B.N.).
Heerspink HJL; George Institute for Global Health, University of New South Wales, Sydney, Australia (M.J.J., S.B., B.N., H.J.L.H., V.P.).; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands (H.J.L.H., D.d.Z.).
Charytan DM; Nephrology Division, NYU School of Medicine and NYU Langone Medical Center, New York (D.M.C.).; Baim Institute for Clinical Research, Boston, MA (D.M.C., C.P.C., B.M.B.).
Edwards R; Janssen Research & Development, LLC, Raritan, NJ (R.E., S.B., G.C., T.S., Y.Y., N.R.).
Agarwal R; Indiana University School of Medicine and VA Medical Center, Indianapolis (R.A.).
Bakris G; Department of Medicine, University of Chicago Medicine, IL (G.B.).
Bull S; Janssen Research & Development, LLC, Raritan, NJ (R.E., S.B., G.C., T.S., Y.Y., N.R.).
Capuano G; Janssen Research & Development, LLC, Raritan, NJ (R.E., S.B., G.C., T.S., Y.Y., N.R.).
de Zeeuw D; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands (H.J.L.H., D.d.Z.).
Greene T; Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City (T.G.).
Levin A; Division of Nephrology, University of British Columbia, Vancouver, Canada (A.L.).
Pollock C; Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St. Leonards, NSW, Australia (C.P.).
Sun T; Janssen Research & Development, LLC, Raritan, NJ (R.E., S.B., G.C., T.S., Y.Y., N.R.).
Wheeler DC; Department of Renal Medicine, UCL Medical School, London, UK (D.C.W.).
Yavin Y; Janssen Research & Development, LLC, Raritan, NJ (R.E., S.B., G.C., T.S., Y.Y., N.R.).
Zhang H; Renal Division of Peking University First Hospital, Beijing, China (H.Z.).
Zinman B; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, ON, Canada (B.Z.).
Rosenthal N; Janssen Research & Development, LLC, Raritan, NJ (R.E., S.B., G.C., T.S., Y.Y., N.R.).
Brenner BM; Baim Institute for Clinical Research, Boston, MA (D.M.C., C.P.C., B.M.B.).; Renal Division and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.M.B.).
Perkovic V; George Institute for Global Health, University of New South Wales, Sydney, Australia (M.J.J., S.B., B.N., H.J.L.H., V.P.).; Royal North Shore Hospital, Sydney, Australia (V.P.).
Pokaż więcej
Źródło :
Circulation [Circulation] 2019 Aug 27; Vol. 140 (9), pp. 739-750. Date of Electronic Publication: 2019 Jul 11.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Canagliflozin/*therapeutic use
Cardiovascular Diseases/*prevention & control
Diabetes Mellitus, Type 2/*pathology
Renal Insufficiency, Chronic/*pathology
Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
Double-Blind Method ; Female ; Humans ; Kidney Failure, Chronic/prevention & control ; Male ; Middle Aged ; Placebo Effect ; Proportional Hazards Models ; Risk ; Secondary Prevention ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke.
Autorzy :
Johnston SC; Dean's Office, Dell Medical School, University of Texas, Austin (S.C.J.).
Elm JJ; Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E., Y.Y.P.).
Easton JD; Department of Neurology, University of California, San Francisco (J.D.E., M.F., A.S.K., K.G.Z.).
Farrant M; Department of Neurology, University of California, San Francisco (J.D.E., M.F., A.S.K., K.G.Z.).
Barsan WG; Department of Emergency Medicine, University of Michigan, Ann Arbor (W.G.B.).
Kim AS; Department of Neurology, University of California, San Francisco (J.D.E., M.F., A.S.K., K.G.Z.).
Lindblad AS; The Emmes Corporation, Rockville, MD (A.S.L.).
Palesch YY; Dean's Office, Dell Medical School, University of Texas, Austin (S.C.J.).
Zurita KG; Department of Neurology, University of California, San Francisco (J.D.E., M.F., A.S.K., K.G.Z.).
Albers GW; Department of Neurology and Neurological Sciences, Stanford Stroke Center, Stanford University, Palo Alto, CA (G.W.A., N.V.).
Cucchiara BL; Department of Neurology, University of Pennsylvania, Philadelphia (B.L.C.).
Kleindorfer DO; Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, OH (D.O.K.).
Lutsep HL; Department of Neurology, Oregon Health and Science University, Portland (H.L.L.).
Pearson C; Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI (C.P.).
Sethi P; Cone Health Comprehensive Stroke Center/Guilford Neurologic Associates, Greensboro, NC (P.S.).
Vora N; Department of Neurology and Neurological Sciences, Stanford Stroke Center, Stanford University, Palo Alto, CA (G.W.A., N.V.).
Pokaż więcej
Corporate Authors :
POINT and Neurological Emergencies Treatment Trials Network Investigators
Źródło :
Circulation [Circulation] 2019 Aug 20; Vol. 140 (8), pp. 658-664. Date of Electronic Publication: 2019 Jun 26.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :
Time Factors*
Aspirin/*therapeutic use
Clopidogrel/*therapeutic use
Drug Therapy, Combination/*adverse effects
Drug-Related Side Effects and Adverse Reactions/*prevention & control
Hemorrhage/*prevention & control
Ischemia/*drug therapy
Ischemic Attack, Transient/*drug therapy
Platelet Aggregation Inhibitors/*therapeutic use
Stroke/*drug therapy
Acute Disease ; Aspirin/adverse effects ; Clinical Protocols ; Clopidogrel/adverse effects ; Hemorrhage/etiology ; Humans ; Platelet Aggregation Inhibitors/adverse effects ; Proportional Hazards Models ; Risk ; Risk Assessment
Czasopismo naukowe
Tytuł :
Microvascular Disease, Peripheral Artery Disease, and Amputation.
Autorzy :
Beckman JA; Division of Cardiovascular Medicine (J.A.B., M.S.D., Q.S.W., A.W.A., M.S.F.), Nashville, TN.
Duncan MS; Division of Cardiovascular Medicine (J.A.B., M.S.D., Q.S.W., A.W.A., M.S.F.), Nashville, TN.
Damrauer SM; Department of Surgery, Perelman School of Medicine, University of Pennsylvania (S.M.D.), Philadelphia.; Corporal Michael Crescenz VA Medical Center (S.M.D.), Philadelphia.
Wells QS; Division of Cardiovascular Medicine (J.A.B., M.S.D., Q.S.W., A.W.A., M.S.F.), Nashville, TN.
Barnett JV; Department of Pharmacology (J.V.B.), Nashville, TN.
Wasserman DH; Vanderbilt University, Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine (D.H.W.), Nashville, TN.
Bedimo RJ; Infectious Disease Section, VA North Texas Health Center and University of Texas Southwestern Medical Center, Dallas (R.J.B.).
Butt AA; Department of Medicine, Weill Cornell Medical College, New York, NY (A.A.B).
Marconi VC; Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, GA (V.C.M.).
Sico JJ; VA Connecticut Healthcare System, West Haven (J.J.S.).
Tindle HA; Division of General Internal Medicine and Public Health (H.A.T.), Nashville, TN.; Yale School of Medicine, Departments of Neurology and Internal Medicine, New Haven, CT. Geriatric Research Education and Clinical Centers, Veterans Affairs Tennessee Valley Healthcare System, Nashville (H.A.T.).
Bonaca MP; University of Colorado School of Medicine and Colorado Prevention Center Clinical Research, Aurora (M.P.B.).
Aday AW; Division of Cardiovascular Medicine (J.A.B., M.S.D., Q.S.W., A.W.A., M.S.F.), Nashville, TN.
Freiberg MS; Division of Cardiovascular Medicine (J.A.B., M.S.D., Q.S.W., A.W.A., M.S.F.), Nashville, TN.
Pokaż więcej
Źródło :
Circulation [Circulation] 2019 Aug 06; Vol. 140 (6), pp. 449-458. Date of Electronic Publication: 2019 Jul 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Amputation*/statistics & numerical data
Microcirculation*
Peripheral Arterial Disease/*surgery
Adult ; Aged ; Comorbidity ; Diabetes Complications/epidemiology ; Disease Susceptibility ; Extremities/blood supply ; Female ; Follow-Up Studies ; Humans ; Ischemia/etiology ; Ischemia/surgery ; Kidney Diseases/epidemiology ; Male ; Middle Aged ; Peripheral Arterial Disease/complications ; Peripheral Arterial Disease/physiopathology ; Peripheral Nervous System Diseases/epidemiology ; Prevalence ; Procedures and Techniques Utilization ; Proportional Hazards Models ; Prospective Studies ; Retinal Diseases/epidemiology ; Risk Factors ; Veterans/statistics & numerical data
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies